日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

学術論文

Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15

MPS-Authors
/persons/resource/persons50655

Yaspo,  Marie-Laure       
Gene Regulation and Systems Biology of Cancer (Marie-Laure Yaspo), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
There are no locators available
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)

iScience_Ng et al_2023.pdf
(出版社版), 5MB

付随資料 (公開)
There is no public supplementary material available
引用

Ng, M., Verboon, L., Issa, H., Bhayadia, R., Vermunt, M. W., Winkler, R., Schüler, L., Alejo, O., Schuschel, K., Regenyi, E., Borchert, D., Heuser, M., Reinhardt, D., Yaspo, M.-L., Heckl, D., & Klusmann, J.-H. (2023). Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15. iScience, 26(10):. doi:10.1016/j.isci.2023.107844.


引用: https://hdl.handle.net/21.11116/0000-000D-DA87-5
要旨
The noncoding genome presents a largely untapped source of new biological insights, including thousands of long noncoding RNA (lncRNA) loci. While lncRNA dysregulation has been reported in myeloid malignancies, their functional relevance remains to be systematically interrogated. We performed CRISPRi screens of lncRNA signatures from normal and malignant hematopoietic cells and identified MYNRL15 as a myeloid leukemia dependency. Functional dissection suggests an RNA-independent mechanism mediated by two regulatory elements embedded in the locus. Genetic perturbation of these elements triggered a long-range chromatin interaction and downregulation of leukemia dependency genes near the gained interaction sites, as well as overall suppression of cancer dependency pathways. Thus, this study describes a new noncoding myeloid leukemia vulnerability and mechanistic concept for myeloid leukemia. Importantly, MYNRL15 perturbation caused strong and selective impairment of leukemia cells of various genetic backgrounds over normal hematopoietic stem and progenitor cells in vitro, and depletion of patient-derived xenografts in vivo.